RE: Salvrx29 Jan 2019 16:57
SalvaRx Group plc ("SalvaRx"), another portfolio investment, has also now completed its sale of 94.2% of SalvaRx Limited to Portage Biotech Inc. ("Portage") in exchange for new shares in Portage which are being distributed to SalvaRx shareholders and which are expected to be delivered shortly. Portage is listed on the CSE (Toronto) and NASDAQ (New York).